Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Cushing's Syndrome Before and After Treatment (CORRECT)

Key facts

Where
Aarhus, DenmarkSee the site

Where in Denmark

  • Department of Endocrinology and Internal MedicineAarhus, DenmarkContact: Simon B Hansen, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University of Aarhus
Trial code
NCT05521529
Record updated
4 April 2025
Original description
The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms.Read full original descriptionShow less

Effects of CORtisol Excess and REmission in Cushing's Syndrome Over Time (CORRECT): A Prospective Non-interventional Cohort Study

The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms.

The hypotheses are:

* Cushing's syndrome negatively impacts health-related quality of life (HRQoL) and physical functioning * Cushing's syndrome is associated with altered circadian rhythms at the whole body level and in peripheral target tissues. * These complications partially reverse following disease control.

Inclusion: New (≤ 2 months) diagnosis of Cushing's syndrome (CS) of endogenous etiology:; ACTH-dependent CS; ACTH-independent CS; Age >18 years; Written informed consent.

Exclusion: Active cancer; Iatrogenic or malignant cause of CS such as adrenocortical carcinoma; Chronic heart failure (New York Heart Association class IV); Liver disease in the form of cirrhosis; Chronic kidney disease Chronic Kidney Disease stage ≥3 (eGFR >30 ml/min); Deemed unable to complete the study safely by investigator.

ClinicalTrials.gov NCT05521529